Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Announces Overnight Marketed Equity Offering

Canada NewsWire June 8, 2017

Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

Canada NewsWire June 5, 2017

Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain

Canada NewsWire May 31, 2017

Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Canada NewsWire May 30, 2017

Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

PR Newswire May 23, 2017

Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

Canada NewsWire May 15, 2017

Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

Canada NewsWire March 17, 2017

Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

Canada NewsWire March 15, 2017

Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Canada NewsWire February 23, 2017

Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

Canada NewsWire February 13, 2017

Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

PR Newswire Asia January 23, 2017

Airline Industry Brief Examines the "Three-P" Approach to Sector Growth in 2017: Passengers, Payments and Profitability

PR Newswire Asia January 23, 2017

Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

Canada NewsWire January 5, 2017

Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

Canada NewsWire December 15, 2016

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

Canada NewsWire December 13, 2016

Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

Canada NewsWire December 5, 2016

Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

Canada NewsWire November 17, 2016

Resverlogix Announces Annual and Special Meeting of Shareholders

Canada NewsWire October 6, 2016

Resverlogix Announces Annual and Special Meeting of Shareholders

PR Newswire October 6, 2016

Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease

Canada NewsWire October 4, 2016